ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2003
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.The Cochrane database of systematic reviews · 2017Pooled it
- Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies.PloS one · 2015Pooled it
- Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.Pathology oncology research : POR · 2007Trial
- Tumour lysis syndrome.Nature reviews. Disease primers · 2024Review
- Review
- Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.BMJ case reports · 2018Article
- Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.OncoTargets and therapy · 2017Review
- Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.Core evidence · 2015Review
- Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.International journal of medical sciences · 2007Review
- Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.Bone marrow transplantation · 2006Article
- Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.Drugs · 2006Review
- Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.Current rheumatology reports · 2004Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
goalsHyperuricaemia (HU) and tumour lysis syndrome (TLS) are complications of acute myeloid/lymphoid leukaemia (AML/ALL) and non-Hodgkin lymphoma (NHL) leading to increased morbidity and mortality. The objective was to assess incremental cost-effectiveness ratios (ICER) of preventing/treating HU and TLS with recombinant urate oxidase, rasburicase (Fasturtec/Elitek). PATIENTS AND
methodsIncidence and costs of HU and TLS were based on a multi-country chart review. Life expectancy at the time of diagnosis was based on published survival rates and age at diagnosis. Reductions of HU/TLS following treatment with rasburicase were based on clinical trial data.
resultsPrevention with rasburicase appears highly cost-effective in children (ICER between Eur 425 and Eur 3054 per life-year saved, LYS). In adults, prevention is more cost-effective in NHL and ALL (maximum ICER of Eur 41383 and Eur 32126 per LYS). Treatment of established HU/TLS with rasburicase is cost-saving in children and highly cost-effective in adults. The results are robust in children. In adults, the prevention strategy appears sensitive to the risk of HU/TLS.
conclusionsIn conclusion, rasburicase, in addition to the demonstrated clinical benefit, is an economically attractive new option in the treatment of HU, both in adults and children. In prevention the drug has an attractive economic profile in children, and is cost-effective in adults with ALL and NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.